<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Cardiovasc Diabetol</journal-id><journal-id journal-id-type="iso-abbrev">Cardiovasc Diabetol</journal-id><journal-title-group><journal-title>Cardiovascular Diabetology</journal-title></journal-title-group><issn pub-type="epub">1475-2840</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27184495</article-id><article-id pub-id-type="pmc">4869394</article-id><article-id pub-id-type="publisher-id">396</article-id><article-id pub-id-type="doi">10.1186/s12933-016-0396-3</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Investigation</subject></subj-group></article-categories><title-group><article-title>Impact of teneligliptin on oxidative stress and endothelial function in type 2 diabetes patients with chronic kidney disease: a case&#x02013;control study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Sagara</surname><given-names>Masaaki</given-names></name><address><email>sgrmsak@dokkyomed.ac.jp</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Suzuki</surname><given-names>Kunihiro</given-names></name><address><phone>+81-282-87-2150</phone><email>kuni-s@dokkyomed.ac.jp</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Aoki</surname><given-names>Chie</given-names></name><address><email>c-aoki@dokkyomed.ac.jp</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Tanaka</surname><given-names>Seiichi</given-names></name><address><email>tanaka-s@dokkyomed.ac.jp</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Taguchi</surname><given-names>Isao</given-names></name><address><email>taguchi@dokkyomed.ac.jp</email></address><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Inoue</surname><given-names>Teruo</given-names></name><address><email>inouet@dokkyomed.ac.jp</email></address><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author"><name><surname>Aso</surname><given-names>Yoshimasa</given-names></name><address><email>y-aso@dokkyomed.ac.jp</email></address><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1"><label/>Department of Endocrinology and Metabolism, Dokkyo Medical University, 880 Kitakobayashi, Mibu, Shimotsugagun, Tochigi 321-0293 Japan </aff><aff id="Aff2"><label/>Department of Cardiology, Dokkyo Medical University, Koshigaya, Saitama Japan </aff><aff id="Aff3"><label/>Department of Cardiovascular Medicine, Dokkyo Medical University, Mibu, Tochigi Japan </aff></contrib-group><pub-date pub-type="epub"><day>17</day><month>5</month><year>2016</year></pub-date><pub-date pub-type="pmc-release"><day>17</day><month>5</month><year>2016</year></pub-date><pub-date pub-type="collection"><year>2016</year></pub-date><volume>15</volume><elocation-id>76</elocation-id><history><date date-type="received"><day>9</day><month>3</month><year>2016</year></date><date date-type="accepted"><day>10</day><month>5</month><year>2016</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s). 2016</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>The aim of the present study was to elucidate the effect of teneligliptin on oxidative stress and endothelial function in Japanese patients with type 2 diabetes and chronic kidney disease (CKD).</p></sec><sec><title>Methods</title><p>Forty-five patients with type 2 diabetes and CKD who received sitagliptin for at least 12&#x000a0;months were randomized to either continue sitagliptin (n&#x000a0;=&#x000a0;23) or switch to teneligliptin (n&#x000a0;=&#x000a0;22) for 24&#x000a0;weeks. The following parameters were evaluated at baseline and after 24&#x000a0;weeks of treatment with continued sitagliptin or teneligliptin: blood pressure, haemoglobin A1c (HbA1c), estimated glomerular filtration rate (eGFR), urinary albumin excretion, endothelial function by reactive hyperaemia index (RHI; EndoPAT<sup>&#x000ae;</sup> system), reactive oxygen metabolites (ROMs) measured by the d-ROMS test, 8-hydroxy-2&#x02032;-deoxyguanosine, urinary liver-type fatty acid binding protein (L-FABP), and urinary 8-isoprostane.</p></sec><sec><title>Results</title><p>The two groups did not significantly differ with regard to age, male-to-female ratio, duration of diabetes, body mass index, HbA1c, eGFR, or urinary albumin excretion levels at baseline. We found no significant differences in changes of HbA1c, eGFR, or urinary albumin excretion levels between the two groups after 24&#x000a0;weeks of treatment. However, treatment with teneligliptin, but not sitagliptin, significantly improved RHI values and was correlated with the percent changes in RHI and d-ROMs.</p></sec><sec><title>Conclusions</title><p>The present study demonstrated that teneligliptin, can improve endothelial function and reduce renal and vascular oxidative stress in patients with type 2 diabetes and CKD, independently of reducing albuminuria or improving glucose control.</p><p><italic>Trial registration</italic> UMIN000017180</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Teneligliptin</kwd><kwd>Sitagliptin</kwd><kwd>Chronic kidney disease</kwd><kwd>Endothelial function</kwd><kwd>Oxidative stress</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2016</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p>The prevalence of type 2 diabetes is increasing rapidly worldwide, affecting an estimated 285 million patients in 2010 and expected to reach 439 million by 2030 [<xref ref-type="bibr" rid="CR1">1</xref>]. This increase has also been seen in Japan, where the majority of the 7.2 million people with diabetes mellitus are aged between 20 and 79, and the number of people with diabetes mellitus will increase to 10.15 million by 2030 [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>]. Chronic kidney disease (CKD) is common in patients with type 2 diabetes mellitus, as well as ischaemic heart disease and stroke [<xref ref-type="bibr" rid="CR4">4</xref>]. In addition, Alan et al. reported that CKD contributes to the development of cardiovascular diseases, and thus it increases the risk of death and cardiovascular events [<xref ref-type="bibr" rid="CR5">5</xref>].</p><p>It has been reported that approximately 40&#x000a0;% of patients with type 2 diabetes mellitus have elevated urinary albumin excretion consistent with underlying renal disease, and 17&#x000a0;% of patients with diabetes have CKD [<xref ref-type="bibr" rid="CR6">6</xref>]. Intensive glycaemic control in type 2 diabetes mellitus significantly reduced the primary composite outcome of microvascular events, mainly as a consequence of a reduction in nephropathy [<xref ref-type="bibr" rid="CR7">7</xref>]. However, options for anti-hyperglycaemic agents in such patients are limited due to safety and tolerability concerns. Metformin, sulfonylureas, and thiazolidinedione are associated with an increased incidence of hypoglycaemia, weight gain, and lactic acidosis in patients with type 2 diabetes and CKD [<xref ref-type="bibr" rid="CR8">8</xref>]. Therefore, many patients with type 2 diabetes and CKD do not achieve or maintain adequate glycaemic control.</p><p>Teneligliptin, a novel dipeptidyl peptidase-4 (DPP-4) inhibitor, is substantially metabolized in the liver, and its serum concentration is not affected by even severe renal impairment [<xref ref-type="bibr" rid="CR9">9</xref>]. By contrast, sitagliptin is cleared primarily by the kidney, with 80&#x000a0;% of oral doses excreted unchanged in the urine [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. Based on its renal clearance, patients with moderate and severe renal insufficiency should receive one-half of the usual clinical dose (50 or 25&#x000a0;mg daily in Japan) [<xref ref-type="bibr" rid="CR11">11</xref>]. In the context of pharmacological characteristics, teneligliptin is advantageous in that the dose remains the same independent of renal function [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR12">12</xref>].</p><p>There have been no reports on the effects of teneligliptin compared to sitagliptin in terms of protective effects on vascular endothelial function, suppression of oxidative stress, and effect on biomarkers of tubulointerstitial kidney damage such as liver fatty acid-binding protein (L-FABP) [<xref ref-type="bibr" rid="CR13">13</xref>] in patients with type 2 diabetes and CKD. In the present study, we aimed to investigate the effect of switching from teneligliptin to sitagliptin for 24&#x000a0;weeks on endothelial function, oxidative stress markers, and biomarkers of tubulointerstitial kidney damage.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Subjects</title><p>Forty-five patients with type 2 diabetes and CKD who received sitagliptin for at least 12&#x000a0;months were randomized to either continue sitagliptin (n&#x000a0;=&#x000a0;23) or switch to teneligliptin (n&#x000a0;=&#x000a0;22) for 24&#x000a0;weeks. All patients had visited the Department of Endocrinology and Metabolism, Dokkyo Medical University Hospital on an outpatient basis for glycaemic control. The entry criteria included (1) age&#x000a0;&#x0003e;20&#x000a0;years old, (2) type 2 diabetes with a haemoglobin A1c (HbA1c)&#x000a0;&#x0003e;6.5&#x000a0;%, (3) CKD [estimated glomerular filtration rate (eGFR)&#x000a0;&#x0003c;60&#x000a0;mL/min/1.73&#x000a0;m<sup>2</sup> or microalbuminuria&#x000a0;&#x0003e;30&#x000a0;mg/g&#x000a0;Cr] [<xref ref-type="bibr" rid="CR14">14</xref>], and (4) treatment with sitagliptin for 1&#x000a0;year or longer. The exclusion criteria were (1) type 1 diabetes, (2) severe diabetic complications such as ketoacidosis, (3) liver dysfunction, (4) pregnant or nursing women and those who might be pregnant, (5) chronic heart failure, (6) haemodialysis, (7) a history of stroke and cardiovascular events, and (8) any patient whom the investigator judged to be inappropriate for this study. Patients were given detailed explanations of the study protocol. Informed consent was obtained from each patient. The study protocol was approved by the Ethical Committee of Dokkyo Medical University. The trial was registered with the University Hospital Medical Information Network (UMIN No. #000017180).</p></sec><sec id="Sec4"><title>Study protocol</title><p>Figure&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref> shows a summary of the study protocol. The present study was an open-label, prospective, randomized study. Patients were randomly divided into two groups: the sitagliptin group continued treatment with sitagliptin and the teneligliptin group switched treatment to teneligliptin at the beginning of the study period. Patients in both groups were assessed for the following parameters before the start of the study and 24&#x000a0;weeks after the continuation of sitagliptin or switch to teneligliptin. No changes were made to the type and dose of glucose-lowering drugs, angiotensin converting enzyme inhibitors, or angiotensin receptor blockers during the study period to avoid possible influences on endothelial function, production of oxidative stress, and blood pressure. These drugs had been prescribed for at least 12&#x000a0;months before the study.<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Study protocol. After outpatients received sitagliptin treatment for a period of 12&#x000a0;months or longer, they were randomized to the sitagliptin group, who continued to be treated with sitagliptin, or the teneligliptin group, whose treatment was switched to teneligliptin at the beginning of the study period</p></caption><graphic xlink:href="12933_2016_396_Fig1_HTML" id="MO1"/></fig></p></sec><sec id="Sec5"><title>Assessment of endothelial function</title><p>Measurement of peripheral vasodilator response with a fingertip pulse amplitude tonometry (PAT) device is emerging as a useful method to assess vascular function [<xref ref-type="bibr" rid="CR15">15</xref>].</p><p>Peripheral endothelial function was assessed by reactive hyperaemia peripheral arterial tonometry (RH-PAT) using an EndoPAT2000 device (Itamar Medical, Caesarea, Israel) as described previously [<xref ref-type="bibr" rid="CR16">16</xref>]. Briefly, a blood pressure cuff was placed on 1 upper arm, while the contralateral arm served as a control. PAT probes were placed on 1 finger of each hand. After a 5-min equilibration period, the cuff was inflated to 60&#x000a0;mmHg above the systolic pressure (if systolic blood pressure was&#x000a0;&#x0003e;140&#x000a0;mmHg) or to 200&#x000a0;mmHg (if systolic blood pressure was&#x000a0;&#x02264;140&#x000a0;mmHg) for 5&#x000a0;min and then deflated to induce reactive hyperaemia.</p><p>RH-PAT values were assessed at baseline and at 6&#x000a0;months. Endothelial dysfunction was defined as reactive hyperaemia index (RHI)&#x000a0;&#x0003c;0.670. Previous studies have demonstrated that the RH-PAT technology has excellent reproducibility [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>].</p></sec><sec id="Sec6"><title>Derivatives of reactive oxygen metabolites (d-ROMs) evaluation</title><p>Oxidative stress is defined as an imbalance between the production of reactive oxygen metabolites (ROMs) and the removal of reactive oxygen species by a variety of endogenous and exogenous antioxidants. In the current study, we assessed oxidative stress using a simple method for the evaluation of ROMs, the recently developed d-ROMs test [<xref ref-type="bibr" rid="CR17">17</xref>]. This assay is relatively inexpensive, can be performed in minutes, and has been used to assess the effectiveness of various antioxidant treatment strategies [<xref ref-type="bibr" rid="CR18">18</xref>]. The d-ROMs test evaluates free radical activity by measuring serum levels of hydroperoxides (Diacron, Grosseto, Italy). The results of the d-ROMs test are expressed in arbitrary units, so-called Caratelli Units (U.CARR), where 1 U.CARR corresponds to 0.08&#x000a0;mg/100&#x000a0;ml&#x000a0;H<sub>2</sub>O<sub>2</sub> [<xref ref-type="bibr" rid="CR19">19</xref>].</p></sec><sec id="Sec7"><title>Other measurements</title><p>Venous blood samples and urinary samples were taken in the morning after an overnight fast.</p><p>We evaluated the following parameters at baseline and after 12 and 24&#x000a0;weeks of treatment: HbA1c, eGFR, and urinary albumin excretion. HbA1c was measured using the automated analyzer &#x0201c;MetaboLead HbA1c&#x0201d; (KYOWA MEDEX CO., LTD., Tokyo, Japan). Serum low-density lipoprotein cholesterol and high-density lipoprotein cholesterol levels were also measured using standard enzymatic methods (MetaboLead HDL-C and MetaboLead LDL-C, KYOWA MEDEX CO., LTD., Tokyo, Japan). Serum triglyceride levels were measured using enzymatic assays (Wako Pure Chemical Industries, Ltd., Osaka). Urinary albumin excretion was measured by immunonephelometry using a kit from Roche Diagnostics (Rotkreuz, Switzerland). eGFR was calculated as 194&#x000a0;&#x000d7;&#x000a0;serum creatinine<sup>&#x02212;1.094</sup>&#x000a0;&#x000d7;&#x000a0;age<sup>&#x02212;0.287</sup> in males, and as 194&#x000a0;&#x000d7;&#x000a0;serum creatinine<sup>&#x02212;1.094</sup>&#x000a0;&#x000d7;&#x000a0;age<sup>&#x02212;0.287</sup>&#x000a0;&#x000d7;&#x000a0;0.739 in females. L-FABP is a urinary biomarker of renal tubular injury and was measured by a two-step sandwich ELISA assay (LSI Medience Corporation, Tokyo, Japan). This biomarker has been evaluated previously in relation to diabetic kidney disease, but the results of different studies were conflicting [<xref ref-type="bibr" rid="CR20">20</xref>&#x02013;<xref ref-type="bibr" rid="CR22">22</xref>]. The other oxidative stress markers, 8-hydroxy-2&#x02032;-deoxyguanosine (8-OHdG) and 8-isoprostane, which were evaluated at baseline and 24&#x000a0;weeks, were measured by LSI Medience Corporation.</p></sec><sec id="Sec8"><title>Statistical analysis</title><p>Data are shown as mean&#x000a0;&#x000b1;&#x000a0;standard deviation. Differences between continuous variables were analysed by the paired <italic>t</italic> test, unpaired <italic>t</italic> test, Mann&#x02013;Whitney U test, and Wilcoxon&#x02019;s matched pairs test as appropriate. Categorical variables were compared by the Chi square test. <italic>P</italic> values&#x000a0;&#x0003c;0.05 were considered significant. All analyses were performed using Prism 6 (GraphPad Software, Inc., San Diego, CA, USA) or StatMate V (Nihon 3B Scientific Inc., Niigata, Japan).</p></sec></sec><sec id="Sec9"><title>Results</title><p>Patients&#x02019; clinical data are shown in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>. There were no significant differences between groups in any clinical or biochemical parameter, including the number of patients in each group with hypertension, being treated for hypertension, with dyslipidaemia, or being treated for dyslipidaemia at baseline. After the 24-weeek treatment period, there were no significant differences between the groups in the levels of HbA1c, eGFR, and (log) urinary albumin excretion (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>a&#x02013;c). Moreover, fasting glucose levels, C-peptide, lipid profiles, and blood pressure did not differ significantly before and after treatment in either group (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). RHI values significantly improved from 1.49&#x000a0;&#x000b1;&#x000a0;0.32 to 1.55&#x000a0;&#x000b1;&#x000a0;0.29 (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.01) in the teneligliptin group, while in the sitagliptin group, RHI values did not differ significantly, from 1.50&#x000a0;&#x000b1;&#x000a0;0.3 to 1.49&#x000a0;&#x000b1;&#x000a0;0.31 (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>a). The percent change in RHI in the teneligliptin group was also significantly greater than that in the sitagliptin group (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>b, <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05). d-ROMs, as a biomarker of oxidative stress, also decreased similarly in the teneligliptin group from 399.8&#x000a0;&#x000b1;&#x000a0;88.4 to 355.5&#x000a0;&#x000b1;&#x000a0;92.0 U.CARR (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.01) (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>a). The percent change in d-ROMs in the teneligliptin group was slightly decreased compared to that in the sitagliptin group (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>b). Furthermore, 8-OHdG was significantly reduced at 24&#x000a0;weeks in the teneligliptin group from 7.1&#x000a0;&#x000b1;&#x000a0;4.9 to 5.4&#x000a0;&#x000b1;&#x000a0;2.9&#x000a0;ng/m&#x000a0;Cre (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>; <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05) compared with the sitagliptin group (6.4&#x000a0;&#x000b1;&#x000a0;1.5&#x000a0;&#x02212;&#x000a0;7.4&#x000a0;&#x000b1;&#x000a0;2.1&#x000a0;ng/mg&#x000a0;Cre). Urinary 8-isoprostane levels slightly increased in both groups at the end of the study, particularly in the sitagliptin group when compared to the levels in the teneligliptin group (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>; <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05).<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Clinical characteristics of the subjects at baseline</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">Teneligliptin</th><th align="left">Sitagliptin</th><th align="left">P value</th></tr></thead><tbody><tr><td align="left">Age (years)</td><td align="left">70.0&#x000a0;&#x000b1;&#x000a0;3.9</td><td align="left">65.4&#x000a0;&#x000b1;&#x000a0;10.7</td><td char="." align="char">0.912</td></tr><tr><td align="left">Sex (M/F)</td><td align="left">22 (10/12)</td><td align="left">23 (12/11)</td><td char="." align="char">0.652</td></tr><tr><td align="left">Body mass index (kg/m<sup>2</sup>)</td><td align="left">22.1&#x000a0;&#x000b1;&#x000a0;3.4</td><td align="left">23.6&#x000a0;&#x000b1;&#x000a0;1.9</td><td char="." align="char">0.209</td></tr><tr><td align="left">HbA1c &#x000a0;% (NGSP)</td><td align="left">8.1&#x000a0;&#x000b1;&#x000a0;1.4</td><td align="left">8.0&#x000a0;&#x000b1;&#x000a0;1.7</td><td char="." align="char">0.739</td></tr><tr><td align="left">Duration of diabetes (years)</td><td align="left">13.2&#x000a0;&#x000b1;&#x000a0;3.0</td><td align="left">12.8&#x000a0;&#x000b1;&#x000a0;6.3</td><td char="." align="char">0.952</td></tr><tr><td align="left">eGFR (mL/min/1.73m<sup>2</sup>)</td><td align="left">43.5&#x000a0;&#x000b1;&#x000a0;15.8</td><td align="left">39.6&#x000a0;&#x000b1;&#x000a0;15.9</td><td char="." align="char">0.394</td></tr><tr><td align="left">Urinary albumin excretion (&#x000b5;g/g Cre)</td><td align="left">418.4 (93.5&#x02013;299.5)</td><td align="left">485.0 (67.0&#x02013;729.3)</td><td char="." align="char">0.750</td></tr><tr><td align="left">Statins n (%)</td><td align="left">16 (72.7&#x000a0;%)</td><td align="left">17 (80.9&#x000a0;%)</td><td char="." align="char">0.627</td></tr><tr><td align="left">ACEI or ARB n (%)</td><td align="left">20 (90.1&#x000a0;%)</td><td align="left">20 (95.2&#x000a0;%)</td><td char="." align="char">0.578</td></tr><tr><td align="left">Biguanide n (%)</td><td align="left">3 (13.6&#x000a0;%)</td><td align="left">4 (19.0&#x000a0;%)</td><td char="." align="char">0.631</td></tr><tr><td align="left">Sulfonylurea or glinide n (%)</td><td align="left">7 (31.8&#x000a0;%)</td><td align="left">9 (42.9&#x000a0;%)</td><td char="." align="char">0.454</td></tr><tr><td align="left">Insulin n (%)</td><td align="left">12 (54.5&#x000a0;%)</td><td align="left">9 (42.9&#x000a0;%)</td><td char="." align="char">0.443</td></tr></tbody></table><table-wrap-foot><p>Data are mean&#x000a0;&#x000b1;&#x000a0;SD or median and interquartile range</p><p>
<italic>ACEI</italic> angiotensin-converting enzyme inhibitor, <italic>ARB</italic> angiotensin II receptor blocker</p></table-wrap-foot></table-wrap><fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>Changes in HbA1c (<bold>a</bold>), eGFR (<bold>b</bold>), and urinary albumin excretion (<bold>c</bold>). There were no significant differences in the levels of HbA1c, eGFR, and urinary albumin excretion between the sitagliptin and teneligliptin treatment groups</p></caption><graphic xlink:href="12933_2016_396_Fig2_HTML" id="MO2"/></fig><table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>Comparison of clinical and biochemical parameters at baseline and 24&#x000a0;weeks</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2"/><th align="left" colspan="2">Teneligliptin (n = 22)</th><th align="left" colspan="2">Sitagliptin (n = 23)</th><th align="left" rowspan="2">P<sup>1</sup> value</th><th align="left" rowspan="2">P<sup>2</sup> value</th></tr><tr><th align="left">Baseline</th><th align="left">24 weeks</th><th align="left">Baseline</th><th align="left">24 weeks</th></tr></thead><tbody><tr><td align="left">HbA1c % (NGSP)</td><td align="left">8.1 &#x000b1; 1.4</td><td align="left">8.0 &#x000b1; 1.2</td><td align="left">8.0 &#x000b1; 1.7</td><td align="left">7.9 &#x000b1; 1.4</td><td char="." align="char">0.27</td><td char="." align="char">0.39</td></tr><tr><td align="left">Fasting glucose (mg/dL)</td><td align="left">161.5 &#x000b1; 49.7</td><td align="left">157.7 &#x000b1; 31.7</td><td align="left">150.0 &#x000b1; 26.3</td><td align="left">161.7 &#x000b1; 33.6</td><td char="." align="char">0.8</td><td char="." align="char">0.19</td></tr><tr><td align="left">C-peptide (ng/mL)</td><td align="left">1.8 &#x000b1; 0.9</td><td align="left">2.0 &#x000b1; 0.6</td><td align="left">2.5 &#x000b1; 1.0</td><td align="left">2.5 &#x000b1; 1.1</td><td char="." align="char">0.32</td><td char="." align="char">0.33</td></tr><tr><td align="left">SBP (mmHg)</td><td align="left">133.3 &#x000b1; 13.4</td><td align="left">132.4 &#x000b1; 14.2</td><td align="left">139.1 &#x000b1; 22.9</td><td align="left">131.4 &#x000b1; 16.8</td><td char="." align="char">0.79</td><td char="." align="char">0.06</td></tr><tr><td align="left">DBP (mmHg)</td><td align="left">76.1 &#x000b1; 11.0</td><td align="left">74.0 &#x000b1; 10.9</td><td align="left">79.3 &#x000b1; 17.0</td><td align="left">75.4 &#x000b1; 12.8</td><td char="." align="char">0.5</td><td char="." align="char">0.07</td></tr><tr><td align="left">LDL-C (mg/dL)</td><td align="left">107.1 &#x000b1; 21.3</td><td align="left">105.3 &#x000b1; 19.4</td><td align="left">98.2 &#x000b1; 21.5</td><td align="left">98.7 &#x000b1; 21.6</td><td char="." align="char">0.71</td><td char="." align="char">0.91</td></tr><tr><td align="left">HDL-C (mg/dL)</td><td align="left">53.4 &#x000b1; 13.2</td><td align="left">50.7 &#x000b1; 12.0</td><td align="left">55.5 &#x000b1; 16.8</td><td align="left">50.1 &#x000b1; 9.1</td><td char="." align="char">0.12</td><td char="." align="char">0.06</td></tr><tr><td align="left">TG (mg/dL)</td><td align="left">120.3 &#x000b1; 41.3</td><td align="left">129.3 &#x000b1; 60.1</td><td align="left">156.1 &#x000b1; 99.9</td><td align="left">149.0 &#x000b1; 70.2</td><td char="." align="char">0.51</td><td char="." align="char">0.61</td></tr><tr><td align="left">eGFR (ml/min<sup>&#x02212;1</sup>/1.73 m<sup>2</sup>)</td><td align="left">43.5 &#x000b1; 15.8</td><td align="left">42.8 &#x000b1; 16.7</td><td align="left">39.6 &#x000b1; 15.9</td><td align="left">39.2 &#x000b1; 16.2</td><td char="." align="char">0.36</td><td char="." align="char">0.77</td></tr><tr><td align="left">Urinary albumin (mg/g Cre)</td><td align="left">141.0 (93.5&#x02013;299.5)</td><td align="left">176.0 (84.5-268.0)</td><td align="left">141.5 (67.0&#x02013;729.3)</td><td align="left">165.5 (52.8-546.0)</td><td char="." align="char">0.58</td><td char="." align="char">0.32</td></tr><tr><td align="left">Log urinary albumin (mg/g Cre)</td><td align="left">2.3 &#x000b1; 0.5</td><td align="left">2.3 &#x000b1; 0.5</td><td align="left">2.3 &#x000b1; 0.6</td><td align="left">2.3 &#x000b1; 0.6</td><td char="." align="char">0.73</td><td char="." align="char">0.25</td></tr><tr><td align="left">Urinary 8-OHdG (ng/mg Cre)</td><td align="left">7.1 &#x000b1; 4.9</td><td align="left">5.4 &#x000b1; 2.9</td><td align="left">6.4 &#x000b1; 1.5</td><td align="left">7.4 &#x000b1; 2.1</td><td char="." align="char">0.03*</td><td char="." align="char">0.1</td></tr><tr><td align="left">Urinary L-FABP (&#x000b5;g/g Cre)</td><td align="left">25.7 (6.3&#x02013;118.0)</td><td align="left">14.5 (7.0&#x02013;64.9)</td><td align="left">48.2 (7.2&#x02013;91.9)</td><td align="left">55.0 (9.6&#x02013;110.8)</td><td char="." align="char">0.02*</td><td char="." align="char">0.22</td></tr><tr><td align="left">Urinary 8-isoprostane (pg/mgCr)</td><td align="left">199.0 (151.5&#x02013;424.0)</td><td align="left">297.0 (212.5&#x02013;440.0)</td><td align="left">258.0 (227.0&#x02013;429.0)</td><td align="left">353.0 (301.0&#x02013;578.0)</td><td char="." align="char">0.06</td><td char="." align="char">0.01*</td></tr></tbody></table><table-wrap-foot><p>Data are mean&#x000a0;&#x000b1;&#x000a0;SD or median and interquartile range</p><p>
<italic>SBP</italic> systolic blood pressure, <italic>DBP</italic> diastolic blood pressure, <italic>LDL</italic>-<italic>C</italic> low-density lipoprotein cholesterol, <italic>HDL</italic> high-density lipoprotein cholesterol, <italic>TG</italic> triglycerides, <italic>eGER</italic> estimated glomerular filtration rate, <italic>8</italic>-<italic>OHdG</italic> 8-hydroxy-2&#x02032;-deoxyguanosine, <italic>L</italic>-<italic>FABP</italic> liver-type fatty acid binding protein</p><p>*&#x000a0;P<sup>1</sup> value:&#x000a0;&#x0003c;0.05, comparison of respective data between baseline and after 24&#x000a0;weeks treatment with teneligliptin</p><p>*&#x000a0;P<sup>2 </sup>value:&#x000a0;&#x0003c;0.05, comparison of respective data between baseline and after 6&#x000a0;month treatment with sitagliptin</p></table-wrap-foot></table-wrap><fig id="Fig3"><label>Fig.&#x000a0;3</label><caption><p>Changes in RHI in both groups (<bold>a</bold>) and the comparison of improvement in RHI (<bold>b</bold>). Percent change in RHI [RHI after 24&#x000a0;weeks&#x02014;RHI before treatment]/RHI before treatment. RHI values significantly improved in the teneligliptin group; the percent change in RHI was also significantly greater in the teneligliptin group. <italic>RHI</italic> reactive hyperaemia index</p></caption><graphic xlink:href="12933_2016_396_Fig3_HTML" id="MO3"/></fig><fig id="Fig4"><label>Fig.&#x000a0;4</label><caption><p>Changes in d-ROMs in both groups (<bold>a</bold>); comparison of percent change in d-ROMs (<bold>b</bold>). Percent change in d-ROMs: [d-ROMs after 24&#x000a0;weeks of treatment&#x02014;d-ROMs before treatment]/baseline d-ROMs value. A biomarker of oxidative stress, d-ROMS, significantly decreased in the teneligliptin group. The percent change in d-ROMs in the teneligliptin group was slightly lower than that in the sitagliptin group</p></caption><graphic xlink:href="12933_2016_396_Fig4_HTML" id="MO4"/></fig></p><p>Baseline values and changes in urine markers of kidney injury (urinary L-FABP) are reported in Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>. Compared with the starting period, teneligliptin, and not sitagliptin, was associated with a significant reduction of urinary L-FABP (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05), whereas urinary &#x003b2;2-microglobulin and N-acetyl b-<sc>d</sc>-glucosaminidase levels did not change in either group (data not shown).</p><p>Figure&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref> shows the percent changes in RHI (the value at the starting of the trial minus that after 24&#x000a0;weeks divided by the starting value) upon treatment with teneligliptin, but not sitagliptin. The percent change in RHI strongly correlated negatively with the percent change in d-ROMs in the teneligliptin group (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>; <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05).<fig id="Fig5"><label>Fig.&#x000a0;5</label><caption><p>Correlation between percent change in RHI and percent change in d-ROMs in the teneligliptin group. The percent change in RHI strongly and negatively correlated with the percent change in d-ROMs in the teneligliptin group (n&#x000a0;=&#x000a0;22)</p></caption><graphic xlink:href="12933_2016_396_Fig5_HTML" id="MO5"/></fig></p></sec><sec id="Sec10"><title>Discussion</title><p>The results of the present study showed that 24-week teneligliptin treatment improved RHI values, as demonstrated by the reduction in d-ROMs and urinary 8-OHdG levels, in patients with type 2 diabetes and CKD who had received sitagliptin for at least 12&#x000a0;months prior to switching to teneligliptin. In addition, we observed that teneligliptin treatment also reduced urinary L-FABP levels regardless of the reduction of urinary albumin excretion. These results suggest that the antioxidative and renoprotective effects of teneligliptin might be stronger than those of other DPP-4 inhibitors, particularly sitagliptin, and might be independent of its blood glucose-lowering effects.</p><p>Mori et al. reported that the DPP-4 inhibitor sitagliptin can prevent progression of diabetic nephropathy by reducing the severity of proteinuria and albuminuria [<xref ref-type="bibr" rid="CR23">23</xref>]. However, the mechanism of DPP-4 inhibitor-induced improvement of albuminuria is unclear. In the present study, since the included patients had already received DPP-4 treatment for at least 12&#x000a0;months, urinary albumin excretion was not reduced in either the sitagliptin or the teneligliptin group. Notably, only switching to teneligliptin, and not sitagliptin continuation, reduced urinary L-FABP at 24&#x000a0;weeks.</p><p>Urinary L-FABP levels have been reported to associate with the histological severity of renal tubulointerstitial lesions in humans [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR24">24</xref>]. Although urinary albumin excretion appears to reflect glomerular damage and subsequently renal tubulointerstitial damage, recently cases of diabetes have been reported in which renal function rapidly decreased without an increase in urinary albumin excretion [<xref ref-type="bibr" rid="CR25">25</xref>]. Therefore, Araki et al. reported that urinary L-FABP might reflect tubulointerstitial damage and predict the progression of deteriorating renal function [<xref ref-type="bibr" rid="CR21">21</xref>]. In addition, increasing urinary L-FABP levels were associated with deteriorating renal function and the high incidence of atherosclerotic cardiovascular disease (ASCVD) in type 2 diabetes. Thus, improvement of urinary L-FABP levels might be clinically useful for patients at high risk for renal disease and ASCVD. Urinary L-FABP is known to be a renoprotective protein localized predominantly in the proximal tubules, which has antioxidant properties and indicates the elevation of oxidative stress markers. One of the mechanisms responsible in part for the reduction of urinary L-FABP levels by teneligliptin treatment might be attenuation of oxidative stress.</p><p>In the present study, we also evaluated levels of urinary 8-OHdG to assess the effect of antioxidative stress on tubulointerstitial kidney damage. Urinary 8-OHdG levels were slightly increased in both treatment groups, whereas urinary 8-OHdG significantly increased from baseline values only in the sitagliptin group. Further long-term studies are needed for more precise evaluation of the effects of teneligliptin on kidney function compared with other DPP-4 inhibitors.</p><p>Previous studies have reported that RHI correlates with vascular endothelial dysfunction and is a risk factor for atherosclerosis and cardiovascular disease [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR26">26</xref>]. Various researchers have reported RHI cutoff values of&#x000a0;&#x0003c;1.82 [<xref ref-type="bibr" rid="CR27">27</xref>],&#x000a0;&#x0003c;1.70 [<xref ref-type="bibr" rid="CR28">28</xref>] and&#x000a0;&#x0003c;1.63 [<xref ref-type="bibr" rid="CR29">29</xref>] in Japanese patients with type 2 diabetes at high risk of atherosclerotic cardiovascular disease. The normal range of RHI values still remains controversial. Therefore, in this present study, the change in RHI values might be an important factor reflecting endothelial function during teneligliptin treatment.</p><p>Endo-PAT is a noninvasive, quantitative, and repeatable technique that captures a beat-to-beat recording of the finger arterial pulse-wave amplitude with pneumatic probes. Therefore, RHI values can be used to evaluate vascular condition and treatment efficacy. According these previous reports, we used RHI values as a reproducible index of endothelial dysfunction. In the present study, teneligliptin treatment was associated with significant improvement of digitally recorded RHI values in type 2 diabetes patients with CKD. Clinical trials in patients with type 2 diabetes demonstrated that DPP-4 inhibitors improve endothelial function, as measured by reactive hyperaemia peripheral arterial tonometry and flow-mediated dilatation [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR30">30</xref>]. However, in this study, we focused on type 2 diabetes patients with chronic kidney disease. We emphasize that this present study is the first report to evaluate the efficacy of teneligliptin on endothelial function and antioxidative effects of teneligliptin in tubulointerstitium and endothelium compared with sitagliptin in patients with type 2 diabetes and chronic kidney disease who are at high risk of ASCVD.</p><p>We recently reported that teneligliptin decreased the proportion of time in hyperglycaemia and increased the proportion of time at normal glucose levels in a 24-h period and significantly improved glucose fluctuations over 24&#x000a0;h [<xref ref-type="bibr" rid="CR31">31</xref>]. By contrast, Nonaka et al. reported that 100&#x000a0;mg/day sitagliptin, but not 50&#x000a0;mg/day, provided substantial 24-h glucose lowering effects [<xref ref-type="bibr" rid="CR32">32</xref>]. The differences between teneligliptin and sitagliptin observed in this study might be due to the fact that the dosage of sitagliptin used in Japan (25&#x000a0;mg/day) is much lower. Moreover, a recent study has shown that teneligliptin has a high potency for inhibiting DPP-4 activity compared with other DPP-4 inhibitors [<xref ref-type="bibr" rid="CR33">33</xref>].</p><p>We also directly observed antioxidative effects of teneligliptin as demonstrated by decreased levels of d-ROMs, a novel global oxidative stress marker that is easy to measure. In addition, we showed that the reduction of d-ROMs levels by teneligliptin treatment was correlated with the amelioration of RHI values. These results suggest that this effect of teneligliptin might be associated with suppression of glucose fluctuation independently affecting renal function. Glucose fluctuation has been reported to cause endothelial dysfunction and oxidative stress generation more than stable high glucose in type 2 diabetes patients [<xref ref-type="bibr" rid="CR34">34</xref>] and in vitro [<xref ref-type="bibr" rid="CR35">35</xref>]. Rizzo et al. also reported that the suppression of glycaemic variability is associated with reduction of oxidative stress and markers of systemic inflammation in patients with type 2 diabetes [<xref ref-type="bibr" rid="CR36">36</xref>]. Since our study focused on the influence of teneligliptin on oxidative stress markers and endothelial function, we measured fasting glucose level and C-peptide but did not examine postprandial glucose, glucose fluctuation, or inflammatory cytokines. However, we have already reported the improvement of glucose fluctuations caused by teneligliptin in Japanese patients with type 2 diabetes [<xref ref-type="bibr" rid="CR31">31</xref>]. Furthermore, Kimura et al. recently demonstrated that a structural feature of teneligliptin, specifically having a sulphur atom within the molecule, was beneficial for radical scavenging. These beneficial effects of teneligliptin may lead to the reduction of oxidative stress [<xref ref-type="bibr" rid="CR37">37</xref>]. Nevertheless, the present study has some limitations. First, the randomized clinical trial used open-label, not double-blind, administration of the study drug; however, the concealment of allocation and the use of an objective end-point assessment strengthened the significance of the results. Second, the number of participants was relatively small, and the study duration was short. Although we measured the expression of ICAM-1/VCAM-1 in both the sitagliptin and teneligliptin treatment groups, ICAM-1/VCAM-1 expression did not significantly decrease in either the teneligliptin or sitagliptin group. Nakagami et al. reported that long-term treatment with teneligliptin significantly decreased ICAM-1 expression in hypertensive rats and that this effect might be due, in part, to alleviating inflammation in the vascular system [<xref ref-type="bibr" rid="CR38">38</xref>]. Longer-term clinical trials might be required to verify the effect of teneligliptin on the expression of ICAM-1/VCAM-1 in type 2 diabetes patients. However, we believe that the significant changes in some biomarkers, which indicate antioxidative effects, by teneligliptin treatment provide novel evidence of DPP-4 inhibitors. Third, the dosage of sitagliptin was relatively small, based on the proper dose for Japanese patients with type 2 diabetes and CKD. Fourth, we did not evaluate the relationship between glucose fluctuation and oxidative stress or RHI values.</p><p>Finally, we do not know whether the antioxidative effects of teneligliptin, as demonstrated in this study, could reduce cardiovascular morbidity in type 2 diabetes patients with CKD. The outcomes of trials of DPP-4 inhibitors, including sitagliptin, saxagliptin, and alogliptin, showed that these agents did not increase or decrease the number of major adverse cardiovascular events [<xref ref-type="bibr" rid="CR39">39</xref>&#x02013;<xref ref-type="bibr" rid="CR42">42</xref>]. Additional information from future experimental studies, as well as clinical studies, with regard to teneligliptin is needed to address these results in patients with type 2 diabetes and CKD.</p></sec><sec id="Sec11"><title>Conclusions</title><p>In conclusion, the present study demonstrated that teneligliptin exhibits beneficial effects on both oxidative stress and endothelial function in Japanese patients with type 2 diabetes and CKD. These findings suggest that teneligliptin might be more useful than other DPP-4 inhibitors in the treatment of type 2 diabetes with CKD.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>8-OHdG</term><def><p>8-hydroxy-2&#x02032;-deoxyguanosine</p></def></def-item><def-item><term>ASCVD</term><def><p>atherosclerotic cardiovascular disease</p></def></def-item><def-item><term>CKD</term><def><p>chronic kidney disease</p></def></def-item><def-item><term>DPP-4</term><def><p>dipeptidyl peptidase-4</p></def></def-item><def-item><term>eGFR</term><def><p>estimated glomerular filtration rate</p></def></def-item><def-item><term>HbA1c</term><def><p>haemoglobin A1c</p></def></def-item><def-item><term>L-FABP</term><def><p>liver-type fatty acid binding protein</p></def></def-item><def-item><term>PAT</term><def><p>peripheral arterial tonometry</p></def></def-item><def-item><term>RHI</term><def><p>reactive hyperaemia index</p></def></def-item><def-item><term>RH-PAT</term><def><p>reactive hyperaemia peripheral arterial tonometry</p></def></def-item><def-item><term>ROMs</term><def><p>reactive oxygen metabolites</p></def></def-item></def-list></glossary><ack><title>Authors&#x02019; contributions</title><p>KS, IT, TI, and YA designed the research; KS, MS, CA, ST, and YA performed the research; KS, MS, CA, and YA analysed data; and KS, MS, and YA wrote the paper. All authors read and approved the final manuscript.</p><sec id="FPar1"><title>Acknowledgements</title><p>The authors thank all the study participants. We acknowledge Ms. Atsumi Kezuka and Ms. Mikie Ogawa for their excellent technical assistance. We would like to thank Editage (<ext-link ext-link-type="uri" xlink:href="http://www.editage.jp">http://www.editage.jp</ext-link>) for English language editing.</p></sec><sec id="FPar2"><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shaw</surname><given-names>JE</given-names></name><name><surname>Sicree</surname><given-names>RA</given-names></name><name><surname>Zimmet</surname><given-names>PZ</given-names></name></person-group><article-title>Global estimates of the prevalence of diabetes for 2010 and 2030</article-title><source>Diabetes Res Clin Pract</source><year>2010</year><volume>87</volume><fpage>4</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1016/j.diabres.2009.10.007</pub-id><pub-id pub-id-type="pmid">19896746</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whiting</surname><given-names>DR</given-names></name><name><surname>Guariguata</surname><given-names>L</given-names></name><name><surname>Weil</surname><given-names>C</given-names></name><name><surname>Shaw</surname><given-names>J</given-names></name></person-group><article-title>IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030</article-title><source>Diabetes Res Clin Pract</source><year>2011</year><volume>94</volume><fpage>311</fpage><lpage>321</lpage><pub-id pub-id-type="doi">10.1016/j.diabres.2011.10.029</pub-id><pub-id pub-id-type="pmid">22079683</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guariguata</surname><given-names>L</given-names></name></person-group><article-title>By the numbers: new estimates from the IDF diabetes atlas update for 2012</article-title><source>Diabetes Res Clin Pract</source><year>2012</year><volume>98</volume><fpage>524</fpage><lpage>525</lpage><pub-id pub-id-type="doi">10.1016/j.diabres.2012.11.006</pub-id><pub-id pub-id-type="pmid">23217268</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kramer</surname><given-names>H</given-names></name><name><surname>Molitch</surname><given-names>ME</given-names></name></person-group><article-title>Screening for kidney disease in adults with diabetes</article-title><source>Diabetes Care</source><year>2005</year><volume>28</volume><fpage>1813</fpage><lpage>1816</lpage><pub-id pub-id-type="doi">10.2337/diacare.28.7.1813</pub-id><pub-id pub-id-type="pmid">15983346</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Go</surname><given-names>AS</given-names></name><name><surname>Chertow</surname><given-names>GM</given-names></name><name><surname>Fan</surname><given-names>D</given-names></name><name><surname>McCulloch</surname><given-names>CE</given-names></name><name><surname>Hsu</surname><given-names>CY</given-names></name></person-group><article-title>Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization</article-title><source>N Engl J Med</source><year>2004</year><volume>351</volume><fpage>1296</fpage><lpage>1305</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa041031</pub-id><pub-id pub-id-type="pmid">15385656</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arjona Ferreira</surname><given-names>JC</given-names></name><name><surname>Marre</surname><given-names>M</given-names></name><name><surname>Barzilai</surname><given-names>N</given-names></name><name><surname>Guo</surname><given-names>H</given-names></name><name><surname>Golm</surname><given-names>GT</given-names></name><name><surname>Sisk</surname><given-names>CM</given-names></name><etal/></person-group><article-title>Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiency</article-title><source>Diabetes Care</source><year>2013</year><volume>36</volume><fpage>1067</fpage><lpage>1073</lpage><pub-id pub-id-type="doi">10.2337/dc12-1365</pub-id><pub-id pub-id-type="pmid">23248197</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>ADVANCE Collaborative Group</collab><name><surname>Patel</surname><given-names>A</given-names></name><name><surname>MacMahon</surname><given-names>S</given-names></name><name><surname>Chalmers</surname><given-names>J</given-names></name><name><surname>Neal</surname><given-names>B</given-names></name><name><surname>Billot</surname><given-names>L</given-names></name><etal/></person-group><article-title>Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes</article-title><source>N Engl J Med</source><year>2008</year><volume>358</volume><fpage>2560</fpage><lpage>2572</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0802987</pub-id><pub-id pub-id-type="pmid">18539916</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inzucchi</surname><given-names>SE</given-names></name></person-group><article-title>Oral antihyperglycemic therapy for type 2 diabetes: scientific review</article-title><source>JAMA</source><year>2002</year><volume>287</volume><fpage>360</fpage><lpage>372</lpage><pub-id pub-id-type="doi">10.1001/jama.287.3.360</pub-id><pub-id pub-id-type="pmid">11790216</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nabeno</surname><given-names>M</given-names></name><name><surname>Akahoshi</surname><given-names>F</given-names></name><name><surname>Kishida</surname><given-names>H</given-names></name><name><surname>Miyaguchi</surname><given-names>I</given-names></name><name><surname>Tanaka</surname><given-names>K</given-names></name><name><surname>Ishii</surname><given-names>S</given-names></name><etal/></person-group><article-title>A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site</article-title><source>Biochem Biophys Res Commun</source><year>2013</year><volume>434</volume><fpage>191</fpage><lpage>196</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2013.03.010</pub-id><pub-id pub-id-type="pmid">23501107</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bergman</surname><given-names>AJ</given-names></name><name><surname>Stevens</surname><given-names>C</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Yi</surname><given-names>B</given-names></name><name><surname>Laethem</surname><given-names>M</given-names></name><name><surname>De Smet</surname><given-names>M</given-names></name><etal/></person-group><article-title>Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers</article-title><source>Clin Ther</source><year>2006</year><volume>28</volume><fpage>55</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1016/j.clinthera.2006.01.015</pub-id><pub-id pub-id-type="pmid">16490580</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>JC</given-names></name><name><surname>Scott</surname><given-names>R</given-names></name><name><surname>Arjona Ferreira</surname><given-names>JC</given-names></name><name><surname>Sheng</surname><given-names>D</given-names></name><name><surname>Gonzalez</surname><given-names>E</given-names></name><name><surname>Davies</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency</article-title><source>Diabetes Obes Metab</source><year>2008</year><volume>10</volume><fpage>545</fpage><lpage>555</lpage><pub-id pub-id-type="doi">10.1111/j.1463-1326.2008.00914.x</pub-id><pub-id pub-id-type="pmid">18518892</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Otsuki</surname><given-names>H</given-names></name><name><surname>Kosaka</surname><given-names>T</given-names></name><name><surname>Nakamura</surname><given-names>K</given-names></name><name><surname>Shimomura</surname><given-names>F</given-names></name><name><surname>Kuwahara</surname><given-names>Y</given-names></name><name><surname>Tsukamoto</surname><given-names>T</given-names></name></person-group><article-title>Safety and efficacy of teneligliptin: a novel DPP-4 inhibitor for hemodialysis patients with type 2 diabetes</article-title><source>Int Urol Nephrol</source><year>2014</year><volume>46</volume><fpage>427</fpage><lpage>432</lpage><pub-id pub-id-type="doi">10.1007/s11255-013-0552-6</pub-id><pub-id pub-id-type="pmid">24014134</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vaidya</surname><given-names>VS</given-names></name><name><surname>Waikar</surname><given-names>SS</given-names></name><name><surname>Ferguson</surname><given-names>MA</given-names></name><name><surname>Collings</surname><given-names>FB</given-names></name><name><surname>Sunderland</surname><given-names>K</given-names></name><name><surname>Gioules</surname><given-names>C</given-names></name><etal/></person-group><article-title>Urinary biomarkers for sensitive and specific detection of acute kidney injury in humans</article-title><source>Clin Transl Sci</source><year>2008</year><volume>1</volume><fpage>200</fpage><lpage>208</lpage><pub-id pub-id-type="doi">10.1111/j.1752-8062.2008.00053.x</pub-id><pub-id pub-id-type="pmid">19212447</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>National Kidney Foundation</collab></person-group><article-title>KDOQI clinical practice guideline for diabetes and CKD: 2012 update</article-title><source>Am J Kidney Dis</source><year>2012</year><volume>60</volume><fpage>850</fpage><lpage>886</lpage><pub-id pub-id-type="doi">10.1053/j.ajkd.2012.07.005</pub-id><pub-id pub-id-type="pmid">23067652</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamburg</surname><given-names>NM</given-names></name><name><surname>Keyes</surname><given-names>MJ</given-names></name><name><surname>Larson</surname><given-names>MG</given-names></name><name><surname>Vasan</surname><given-names>RS</given-names></name><name><surname>Schnabel</surname><given-names>R</given-names></name><name><surname>Pryde</surname><given-names>MM</given-names></name><etal/></person-group><article-title>Cross-sectional relations of digital vascular function to cardiovascular risk factors in the Framingham Heart Study</article-title><source>Circulation</source><year>2008</year><volume>13</volume><fpage>2467</fpage><lpage>2474</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.107.748574</pub-id><pub-id pub-id-type="pmid">18458169</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsubara</surname><given-names>J</given-names></name><name><surname>Sugiyama</surname><given-names>S</given-names></name><name><surname>Akiyama</surname><given-names>E</given-names></name><name><surname>Iwashita</surname><given-names>S</given-names></name><name><surname>Kurokawa</surname><given-names>H</given-names></name><name><surname>Ohba</surname><given-names>K</given-names></name><etal/></person-group><article-title>Dipeptidyl peptidase-4 inhibitor, sitagliptin, improves endothelial dysfunction in association with its anti-inflammatory effects in patients with coronary artery disease and uncontrolled diabetes</article-title><source>Circulation</source><year>2013</year><volume>77</volume><fpage>1337</fpage><lpage>1344</lpage><pub-id pub-id-type="doi">10.1253/circj.CJ-12-1168</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taguchi</surname><given-names>I</given-names></name><name><surname>Toyoda</surname><given-names>S</given-names></name><name><surname>Takano</surname><given-names>K</given-names></name><name><surname>Arikawa</surname><given-names>T</given-names></name><name><surname>Kikuchi</surname><given-names>M</given-names></name><name><surname>Ogawa</surname><given-names>M</given-names></name><etal/></person-group><article-title>Irbesartan, an angiotensin receptor blocker, exhibits metabolic, anti-inflammatory and antioxidative effects in patients with high-risk hypertension</article-title><source>Hypertens Res</source><year>2013</year><volume>36</volume><fpage>608</fpage><lpage>613</lpage><pub-id pub-id-type="doi">10.1038/hr.2013.3</pub-id><pub-id pub-id-type="pmid">23425956</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cornelli</surname><given-names>U</given-names></name><name><surname>Terranova</surname><given-names>R</given-names></name><name><surname>Luca</surname><given-names>S</given-names></name><name><surname>Cornelli</surname><given-names>M</given-names></name><name><surname>Alberti</surname><given-names>A</given-names></name></person-group><article-title>Bioavailability and antioxidant activity of some food supplements in men and women using the D-Roms test as a marker of oxidative stress</article-title><source>J Nutr</source><year>2001</year><volume>131</volume><fpage>3208</fpage><lpage>3211</lpage><pub-id pub-id-type="pmid">11739867</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cesarone</surname><given-names>MR</given-names></name><name><surname>Belcaro</surname><given-names>G</given-names></name><name><surname>Carratelli</surname><given-names>M</given-names></name><name><surname>Cornelli</surname><given-names>U</given-names></name><name><surname>De Sanctis</surname><given-names>MT</given-names></name><name><surname>Incandela</surname><given-names>L</given-names></name><etal/></person-group><article-title>A simple test to monitor oxidative stress</article-title><source>Int Angiol</source><year>1999</year><volume>18</volume><fpage>127</fpage><lpage>130</lpage><pub-id pub-id-type="pmid">10424368</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chou</surname><given-names>KM</given-names></name><name><surname>Lee</surname><given-names>CC</given-names></name><name><surname>Chen</surname><given-names>CH</given-names></name><name><surname>Sun</surname><given-names>CY</given-names></name></person-group><article-title>Clinical value of NGAL, L-FABP and albuminuria in predicting GFR decline in type 2 diabetes mellitus patients</article-title><source>PLoS ONE</source><year>2013</year><volume>8</volume><fpage>e54863</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0054863</pub-id><pub-id pub-id-type="pmid">23349979</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Araki</surname><given-names>S</given-names></name><name><surname>Haneda</surname><given-names>M</given-names></name><name><surname>Koya</surname><given-names>D</given-names></name><name><surname>Sugaya</surname><given-names>T</given-names></name><name><surname>Isshiki</surname><given-names>K</given-names></name><name><surname>Kume</surname><given-names>S</given-names></name><etal/></person-group><article-title>Predictive effects of urinary liver-type fatty acid-binding protein for deteriorating renal function and incidence of cardiovascular disease in type 2 diabetic patients without advanced nephropathy</article-title><source>Diabetes Care</source><year>2013</year><volume>36</volume><fpage>1248</fpage><lpage>1253</lpage><pub-id pub-id-type="doi">10.2337/dc12-1298</pub-id><pub-id pub-id-type="pmid">23223350</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamijo-Ikemori</surname><given-names>A</given-names></name><name><surname>Sugaya</surname><given-names>T</given-names></name><name><surname>Yasuda</surname><given-names>T</given-names></name><name><surname>Kawata</surname><given-names>T</given-names></name><name><surname>Ota</surname><given-names>A</given-names></name><name><surname>Tatsunami</surname><given-names>S</given-names></name><etal/></person-group><article-title>Clinical significance of urinary liver-type fatty acid-binding protein in diabetic nephropathy of type 2 diabetic patients</article-title><source>Diabetes Care</source><year>2011</year><volume>34</volume><fpage>691</fpage><lpage>696</lpage><pub-id pub-id-type="doi">10.2337/dc10-1392</pub-id><pub-id pub-id-type="pmid">21273494</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mori</surname><given-names>H</given-names></name><name><surname>Okada</surname><given-names>Y</given-names></name><name><surname>Arao</surname><given-names>T</given-names></name><name><surname>Tanaka</surname><given-names>Y</given-names></name></person-group><article-title>Sitagliptin improves albuminuria in patients with type 2 diabetes mellitus</article-title><source>J Diabetes Investig</source><year>2014</year><volume>5</volume><fpage>313</fpage><lpage>319</lpage><pub-id pub-id-type="doi">10.1111/jdi.12142</pub-id><pub-id pub-id-type="pmid">24843780</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamijyo</surname><given-names>A</given-names></name><name><surname>Kimura</surname><given-names>K</given-names></name><name><surname>Sugaya</surname><given-names>T</given-names></name><name><surname>Yamanouchi</surname><given-names>M</given-names></name><name><surname>Hirano</surname><given-names>N</given-names></name><name><surname>Hirata</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Urinary fatty acid-binding protein as a new clinical marker of the progression of chronic renal disease</article-title><source>J Lab Clin Med</source><year>2004</year><volume>143</volume><fpage>23</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1016/j.lab.2003.08.001</pub-id><pub-id pub-id-type="pmid">14749682</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perkins</surname><given-names>BA</given-names></name><name><surname>Ficociello</surname><given-names>LH</given-names></name><name><surname>Ostrander</surname><given-names>BE</given-names></name><name><surname>Silva</surname><given-names>KH</given-names></name><name><surname>Weinberg</surname><given-names>J</given-names></name><name><surname>Warram</surname><given-names>JH</given-names></name><etal/></person-group><article-title>Microalbuminuria and the risk for early progressive renal function decline in type 1 diabetes</article-title><source>J Am Soc Nephrol</source><year>2007</year><volume>18</volume><fpage>1353</fpage><lpage>1361</lpage><pub-id pub-id-type="doi">10.1681/ASN.2006080872</pub-id><pub-id pub-id-type="pmid">17329575</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Torimoto</surname><given-names>K</given-names></name><name><surname>Okada</surname><given-names>Y</given-names></name><name><surname>Mori</surname><given-names>H</given-names></name><name><surname>Tanaka</surname><given-names>Y</given-names></name></person-group><article-title>Relationship between fluctuations in glucose levels measured by continuous glucose monitoring and vascular endothelial dysfunction in type 2 diabetes mellitus</article-title><source>Cardiovasc Diabetol</source><year>2013</year><volume>12</volume><fpage>1</fpage><pub-id pub-id-type="doi">10.1186/1475-2840-12-1</pub-id><pub-id pub-id-type="pmid">23280391</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsuzawa</surname><given-names>Y</given-names></name><name><surname>Sugiyama</surname><given-names>S</given-names></name><name><surname>Sugamura</surname><given-names>K</given-names></name><name><surname>Nozaki</surname><given-names>T</given-names></name><name><surname>Ohba</surname><given-names>K</given-names></name><name><surname>Konishi</surname><given-names>M</given-names></name><etal/></person-group><article-title>Digital assessment of endothelial function and ischemic heart disease in women</article-title><source>J Am Coll Cardiol</source><year>2010</year><volume>55</volume><fpage>1688</fpage><lpage>1696</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2009.10.073</pub-id><pub-id pub-id-type="pmid">20394872</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsuzawa</surname><given-names>Y</given-names></name><name><surname>Sugiyama</surname><given-names>S</given-names></name><name><surname>Sumida</surname><given-names>H</given-names></name><name><surname>Sugamura</surname><given-names>K</given-names></name><name><surname>Nozaki</surname><given-names>T</given-names></name><name><surname>Ohba</surname><given-names>K</given-names></name><etal/></person-group><article-title>Peripheral endothelial function and cardiovascular events in high-risk patients</article-title><source>J Am Heart Assoc</source><year>2013</year><volume>25</volume><fpage>e000426</fpage><pub-id pub-id-type="doi">10.1161/JAHA.113.000426</pub-id><pub-id pub-id-type="pmid">24275629</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fujisue</surname><given-names>K</given-names></name><name><surname>Sugiyama</surname><given-names>S</given-names></name><name><surname>Ono</surname><given-names>T</given-names></name><name><surname>Matsuzawa</surname><given-names>Y</given-names></name><name><surname>Akiyama</surname><given-names>E</given-names></name><name><surname>Sugamura</surname><given-names>K</given-names></name><etal/></person-group><article-title>Effects of endothelial dysfunction on residual platelet aggregability after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease</article-title><source>Circ Cardiovasc Interv</source><year>2013</year><volume>6</volume><fpage>452</fpage><lpage>459</lpage><pub-id pub-id-type="doi">10.1161/CIRCINTERVENTIONS.112.000278</pub-id><pub-id pub-id-type="pmid">23922147</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakamura</surname><given-names>K</given-names></name><name><surname>Oe</surname><given-names>H</given-names></name><name><surname>Kihara</surname><given-names>H</given-names></name><name><surname>Shimada</surname><given-names>K</given-names></name><name><surname>Fukuda</surname><given-names>S</given-names></name><name><surname>Watanabe</surname><given-names>K</given-names></name><etal/></person-group><article-title>DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study</article-title><source>Cardiovasc Diabetol</source><year>2014</year><volume>30</volume><fpage>110</fpage><pub-id pub-id-type="doi">10.1186/s12933-014-0110-2</pub-id><pub-id pub-id-type="pmid">25074318</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanaka</surname><given-names>S</given-names></name><name><surname>Suzuki</surname><given-names>K</given-names></name><name><surname>Aoki</surname><given-names>C</given-names></name><name><surname>Niitani</surname><given-names>M</given-names></name><name><surname>Kato</surname><given-names>K</given-names></name><name><surname>Tomotsune</surname><given-names>T</given-names></name><name><surname>Aso</surname><given-names>Y</given-names></name></person-group><article-title>Add-on treatment with teneligliptin ameliorates glucose fluctuations and improves glycemic control index in Japanese patients with type 2 diabetes on insulin therapy</article-title><source>Diabetes Technol Ther</source><year>2014</year><volume>16</volume><fpage>840</fpage><lpage>845</lpage><pub-id pub-id-type="doi">10.1089/dia.2014.0095</pub-id><pub-id pub-id-type="pmid">25144424</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nonaka</surname><given-names>K</given-names></name><name><surname>Tsubouchi</surname><given-names>H</given-names></name><name><surname>Okayama</surname><given-names>K</given-names></name><name><surname>Fukao</surname><given-names>Y</given-names></name><name><surname>Johnson-Levonas</surname><given-names>AO</given-names></name><name><surname>Amatruda</surname><given-names>JM</given-names></name></person-group><article-title>Effects of once-daily sitagliptin on 24-h glucose control following 4&#x000a0;weeks of treatment in Japanese patients with type 2 diabetes mellitus</article-title><source>Horm Metab Res</source><year>2009</year><volume>41</volume><fpage>232</fpage><lpage>237</lpage><pub-id pub-id-type="doi">10.1055/s-0028-1100413</pub-id><pub-id pub-id-type="pmid">19253204</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kadowaki</surname><given-names>T</given-names></name><name><surname>Kondo</surname><given-names>K</given-names></name></person-group><article-title>Efficacy, safety and dose-response relationship of teneligliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus</article-title><source>Diabetes Obes Metab</source><year>2013</year><volume>15</volume><fpage>810</fpage><lpage>818</lpage><pub-id pub-id-type="doi">10.1111/dom.12092</pub-id><pub-id pub-id-type="pmid">23464664</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ceriello</surname><given-names>A</given-names></name><name><surname>Esposito</surname><given-names>K</given-names></name><name><surname>Piconi</surname><given-names>L</given-names></name><name><surname>Ihnat</surname><given-names>MA</given-names></name><name><surname>Thorpe</surname><given-names>JE</given-names></name><name><surname>Testa</surname><given-names>R</given-names></name><etal/></person-group><article-title>Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients</article-title><source>Diabetes</source><year>2008</year><volume>57</volume><fpage>1349</fpage><lpage>1354</lpage><pub-id pub-id-type="doi">10.2337/db08-0063</pub-id><pub-id pub-id-type="pmid">18299315</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suzuki</surname><given-names>K</given-names></name><name><surname>Olah</surname><given-names>G</given-names></name><name><surname>M&#x000f3;dis</surname><given-names>K</given-names></name><name><surname>Colletta</surname><given-names>C</given-names></name><name><surname>Kulp</surname><given-names>G</given-names></name><name><surname>Ger&#x000f6;</surname><given-names>D</given-names></name><etal/></person-group><article-title>Hydrogen sulfide replacement therapy protects the vascular endothelium in hyperglycemia by preserving mitochondrial function</article-title><source>Proc Natl Acad Sci USA</source><year>2011</year><volume>108</volume><fpage>13829</fpage><lpage>13834</lpage><pub-id pub-id-type="doi">10.1073/pnas.1105121108</pub-id><pub-id pub-id-type="pmid">21808008</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rizzo</surname><given-names>MR</given-names></name><name><surname>Barbieri</surname><given-names>M</given-names></name><name><surname>Marfella</surname><given-names>R</given-names></name><name><surname>Paolisso</surname><given-names>G</given-names></name></person-group><article-title>Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition</article-title><source>Diabetes Care</source><year>2012</year><volume>35</volume><fpage>2076</fpage><lpage>2082</lpage><pub-id pub-id-type="doi">10.2337/dc12-0199</pub-id><pub-id pub-id-type="pmid">22688551</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kimura</surname><given-names>S</given-names></name><name><surname>Inoguchi</surname><given-names>T</given-names></name><name><surname>Yamasaki</surname><given-names>T</given-names></name><name><surname>Yamato</surname><given-names>M</given-names></name><name><surname>Ide</surname><given-names>M</given-names></name><name><surname>Sonoda</surname><given-names>N</given-names></name><etal/></person-group><article-title>A novel DPP-4 inhibitor teneligliptin scavenges hydroxyl radicals: in vitro study evaluated by electron spin resonance spectroscopy and in vivo study using DPP-4 deficient rats</article-title><source>Metabolism</source><year>2016</year><volume>65</volume><fpage>138</fpage><lpage>145</lpage><pub-id pub-id-type="doi">10.1016/j.metabol.2015.10.030</pub-id><pub-id pub-id-type="pmid">26892525</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakagami</surname><given-names>H</given-names></name><name><surname>Pang</surname><given-names>Z</given-names></name><name><surname>Shimosato</surname><given-names>T</given-names></name><name><surname>Moritani</surname><given-names>T</given-names></name><name><surname>Kurinami</surname><given-names>H</given-names></name><name><surname>Koriyama</surname><given-names>H</given-names></name><etal/></person-group><article-title>The dipeptidyl peptidase-4 inhibitor teneligliptin improved endothelial dysfunction and insulin resistance in the SHR/NDmcr-cp rat model of metabolic syndrome</article-title><source>Hypertens Res</source><year>2014</year><volume>37</volume><fpage>629</fpage><lpage>635</lpage><pub-id pub-id-type="doi">10.1038/hr.2014.53</pub-id><pub-id pub-id-type="pmid">24621463</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scirica</surname><given-names>BM</given-names></name><name><surname>Bhatt</surname><given-names>DL</given-names></name><name><surname>Braunwald</surname><given-names>E</given-names></name><name><surname>Steg</surname><given-names>PG</given-names></name><name><surname>Davidson</surname><given-names>J</given-names></name><name><surname>Hirshberg</surname><given-names>B</given-names></name><etal/></person-group><article-title>SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus</article-title><source>N Engl J Med</source><year>2013</year><volume>369</volume><fpage>1317</fpage><lpage>1326</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1307684</pub-id><pub-id pub-id-type="pmid">23992601</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>White</surname><given-names>WB</given-names></name><name><surname>Cannon</surname><given-names>CP</given-names></name><name><surname>Heller</surname><given-names>SR</given-names></name><name><surname>Nissen</surname><given-names>SE</given-names></name><name><surname>Bergenstal</surname><given-names>RM</given-names></name><name><surname>Bakris</surname><given-names>GL</given-names></name><etal/></person-group><article-title>EXAMINE investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes</article-title><source>N Engl J Med</source><year>2013</year><volume>369</volume><fpage>1327</fpage><lpage>1335</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1305889</pub-id><pub-id pub-id-type="pmid">23992602</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Green</surname><given-names>JB</given-names></name><name><surname>Bethel</surname><given-names>MA</given-names></name><name><surname>Armstrong</surname><given-names>PW</given-names></name><name><surname>Buse</surname><given-names>JB</given-names></name><name><surname>Engel</surname><given-names>SS</given-names></name><name><surname>Garg</surname><given-names>J</given-names></name><etal/></person-group><article-title>TECOS study group. effect of sitagliptin on cardiovascular outcomes in type 2 diabetes</article-title><source>N Engl J Med</source><year>2015</year><volume>373</volume><fpage>232</fpage><lpage>242</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1501352</pub-id><pub-id pub-id-type="pmid">26052984</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fisman</surname><given-names>EZ</given-names></name><name><surname>Tenenbaum</surname><given-names>A</given-names></name></person-group><article-title>Antidiabetic treatment with gliptins: focus on cardiovascular effects and outcomes</article-title><source>Cardiovasc Diabetol</source><year>2015</year><volume>14</volume><fpage>129</fpage><pub-id pub-id-type="doi">10.1186/s12933-015-0294-0</pub-id><pub-id pub-id-type="pmid">26415691</pub-id></element-citation></ref></ref-list></back></article>